An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: An apparent clinical relationship between pain and depression has long been recognized, which makes an enormous impact on the individual health care. At present, the practical implication of such overlapping symptomatology between pain and depression is not clear, but the prevalence estimates for depression are substantially inflated among patients with chronic pain and vice versa. This interaction has been labeled as the depression-pain syndrome or depression-pain dyad. AREAS COVERED: This article discusses the neurobiological substrates and neuroanatomical pathways involved in pain-depression dyad along with newer therapeutic targets. EXPERT OPINION: Several key themes emerged from our review of the relationship between depression and pain. First, the diagnosis of depression in pain or vice versa is particularly challenging, and the development of better diagnostic framework that involves both pain and depression is particularly required. Secondly, the entwined relationship between pain and depression supports the possibility of common coactivating factors that results in their neurophysiological overlap. A broad understanding of the role played by the central nervous system (CNS) in the processing of pain and depression may eventually lead to the introduction of triple reuptake inhibitors, agomelatine, vilazodone and ketamine with novel mechanism of action, hence appear to be of promising potential for pain with depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006) · European Journal of Pain · doi:10.1016/j.ejpain.2005.06.009 · Cited by 5,486
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 2×
“4 Role of cytokines Both patients with depressive symptoms and patients with pain disorders often display enhanced cytokine levels including interleukin-6 (IL-6), C-reactive protein (CRP), interleukin-1-beta (IL-1b) and tumor necrosis factor alpha (TNF-a) [58,145,146].”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Levomilnacipran (Forest) are expected to gain first approval for depression in 2013 [190].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Depression and Pain Comorbidity: A Literature Review
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.20.2433 · Cited by 3,463
Human brain mechanisms of pain perception and regulation in health and disease
Apkarian, A. V., Bushnell, M. C., Treede, R., & Zubieta, J. (2005) · European Journal of Pain · doi:10.1016/j.ejpain.2004.11.001 · Cited by 3,126
Millan, M. J. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00009-6 · Cited by 3,035
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry
Basbaum, A. I., & Fields, H. L. (1984) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.07.030184.001521 · Cited by 2,687
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059 · cited 1×
“Beyond the serotonin and norepinephrine, a role for dopamine in the treatment of depression has been postulated as well [95,96].”
BackgroundPersistent Pain and Well-being: A World Health Organization Study in Primary Care
Gureje, O., Von Korff, M., Simon, G. E., & Gater, R. (1998) · JAMA · doi:10.1001/jama.280.2.147 · Cited by 1,496 · cited 3×
“Physical symptoms typically include medically unexplained pain [25,26] and patients with physical pain are more likely to develop depression [25,27,28] vis à vis depression is likewise a powerful predictor of pain, particularly persistent pain [12,23,29] and has been shown to result in decreased pain threshold and inc…”
BackgroundAn international study of the relation between somatic symptoms and depression
Simon, G. E., VonKorff, M., Piccinelli, M., Fullerton, C., & Ormel, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411801 · Cited by 1,303 · cited 2×
“…& Romado 1984 Haley et al. 1985 Katon et al. 1985 Fishbain et al. 1986 Benjamin et al. 1988 Lobo et al.1996 Vaeroy & Merskey 1997 Gureje et al. 1998 Simon et al. 1999 Wilson et al. 2001 Bair 2004 Husain et al. 2007 Kroenke et al. 2008 Lee et al. 2009 Agüera-Ortiz et al. 2010 Ho et al. 2011 Wong et…”
BackgroundThe Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 2×
“Several symptoms observed in depression, including impaired motivation, concentration and pleasure result from an attenuation of dopaminergic neurotransmission, strengthening the hypothesis that DA also regulates mood [95].”
BackgroundThe Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 1×
“Among all the three key neurotransmitters involved in both pain and depression, that is, serotonin, norepinephrine and dopamine, the serotonin hypothesis of depression is over 40 years old [77].”
BackgroundLower Hippocampal Volume in Patients Suffering From Depression: A Meta-Analysis
Campbell, S., Marriott, M., Nahmias, C., & MacQueen, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.598 · Cited by 1,156
Chronic pain in Australia: a prevalence study.
Blyth, F. M., March, L. M., Brnabic, A. J. M., Jorm, L. R., Williamson, M., & Cousins, M. J. (2001) · Pain · doi:10.1016/s0304-3959(00)00355-9 · Cited by 1,096
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“2 Nonbiogenic amine-based therapeutic strategies Although there is a formidable body of preclinical and clinical data strengthening the association between pain--depression symptomatology and alterations in aminergic transmission, both the modest remission rates (estimated at 25 -- 30%) and significant proportion (est…”
BackgroundA Swedish National Twin Study of Lifetime Major Depression
Kendler, K. S., Gatz, M., Gardner, C. O., & Pedersen, N. L. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.109 · Cited by 794 · cited 1×
“Similar assumptions have been made for the genetic contribution in depression [175].”
BackgroundElevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome
Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., Lopez, Y., & Mackillip, F. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371106 · Cited by 679
Chronic Pain and Psychopathology: Research Findings and Theoretical Considerations
Dersh, J., Polatin, P. B., & Gatchel, R. J. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200209000-00010 · Cited by 676
Patients presenting with somatic complaints: epidemiology, psychiatric co‐morbidity and management
Kroenke, K. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.140 · Cited by 624
Corticosteroids in relation to fear, anxiety and psychopathology
Korte, S. M. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00002-1 · Cited by 607 · cited 3×
“2 Nonbiogenic amine-based therapeutic strategies Although there is a formidable body of preclinical and clinical data strengthening the association between pain--depression symptomatology and alterations in aminergic transmission, both the modest remission rates (estimated at 25 -- 30%) and significant proportion (est…”
BackgroundChronic back pain and major depression in the general Canadian population
Currie, S. R., & Wang, J. (2004) · Pain · doi:10.1016/j.pain.2003.09.015 · Cited by 573
Sarandol, A., Sarandol, E., Eker, S. S., Erdinc, S., Vatansever, E., & Kirli, S. (2007) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.829 · Cited by 486
Khanzode, S. D., Dakhale, G. N., Khanzode, S. S., Saoji, A., & Palasodkar, R. (2003) · Redox Report · doi:10.1179/135100003225003393 · Cited by 458 · cited 2×
“Patients with fibromyalgia exhibit significantly elevated levels of CSF SP, with two- to three-fold higher values among the patients than the controls [116-120] Role of oxidative and nitrosative stress Depression: human studies have reported a number of oxidative disturbances in patients with major depression as sugge…”
BackgroundComorbidity of Fibromyalgia and Psychiatric Disorders
Arnold, L. M., Hudson, J. I., Keck, P. E., Auchenbach, M. B., Javaras, K. N., & Hess, E. V. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0807 · Cited by 382 · cited 1×
“Twin and population studies suggest that pain (fibromyalgia) is influenced by genetic and environmental factors and coaggregate in families [173,174].”
BackgroundImpact of pain on depression treatment response in primary care
Bair, M. J., Robinson, R. L., Eckert, G. J., Stang, P. E., Croghan, T. W., & Kroenke, K. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000106883.94059.c5 · Cited by 371
Gureje, O., Von Korff, M., Kola, L., Demyttenaere, K., He, Y., Posada-Villa, J., Lepine, J. P., Angermeyer, M. C., Levinson, D., de Girolamo, G., et al. (2008) · Pain · doi:10.1016/j.pain.2007.05.005 · Cited by 337
Herken, H., Gurel, A., Selek, S., Armutcu, F., Ozen, M. E., Bulut, M., Kap, O., Yumru, M., Savas, H. A., & Akyol, O. (2007) · Archives of Medical Research · doi:10.1016/j.arcmed.2006.10.005 · Cited by 322
Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder
Eller, T., Vasar, V., Shlik, J., & Maron, E. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.015 · Cited by 290 · cited 2×
“Patients with fibromyalgia exhibit significantly elevated levels of CSF SP, with two- to three-fold higher values among the patients than the controls [116-120] Role of oxidative and nitrosative stress Depression: human studies have reported a number of oxidative disturbances in patients with major depression as sugge…”
BackgroundCerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients
John Mann, J., & Malone, K. M. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00217-x · Cited by 278
Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · cited 1×
“2 Nonbiogenic amine-based therapeutic strategies Although there is a formidable body of preclinical and clinical data strengthening the association between pain--depression symptomatology and alterations in aminergic transmission, both the modest remission rates (estimated at 25 -- 30%) and significant proportion (est…”
BackgroundThe role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245 · cited 2×
“Studies indicate an important role of mesolimbic dopamine in moderating motivation and reward-related behavior that are typically disrupted in depression [97,98].”
BackgroundEconomic burden of chronic pain
Phillips, C. J. (2006) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.6.5.591 · Cited by 139 · cited 1×
“Pain is also one of themost common and among themost personally compelling reasons for seeking medical attention, and therefore represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to > 60% [8-13].”
BackgroundGałecki, P., Szemraj, J., Bieńkiewicz, M., Zboralski, K., & Gałecka, E. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1014 · Cited by 124
Pain is a salient “stressor” that is mediated by corticotropin-releasing factor-1 receptors
Hummel, M., Cummons, T., Lu, P., Mark, L., Harrison, J. E., Kennedy, J. D., & Whiteside, G. T. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.05.001 · Cited by 43
Cited by
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
Sanabria-Mazo, J. P., Colomer-Carbonell, A., Fernández-Vázquez, Ó., Noboa-Rocamora, G., Cardona-Ros, G., McCracken, L. M., Montes-Pérez, A., Castaño-Asins, J. R., Edo, S., Borràs, X., et al. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1200685 · Cited by 56
Aragonès, E., Rambla, C., López-Cortacans, G., Tomé-Pires, C., Sánchez-Rodríguez, E., Caballero, A., & Miró, J. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.004 · Cited by 50
Cabrera-León, A., Cantero-Braojos, M. Á., Garcia-Fernandez, L., & Guerra de Hoyos, J. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020913 · Cited by 29
“First, from a neurological point of view, pain and depression interact in a complex relationship of situational and physiological connections that is not yet fully understood.(45) Second, depression and anxiety were measured together in our study through the same variable.”
Background
Metadata
- Authors
- Chopra, K., & Arora, V.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2013-12-03
- Volume
- 18
- Issue
- 2
- Pages
- 159-176
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W1991298548
- Cited by
- 71
- References
- 39
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.